Scores range from 0 to 72. A score of more than 10 generally translates to “moderate-to-severe.” A score of more than 40 is rare. Usually, the higher your PASI score, the lower your quality of ...

These data indicate that "prolonged [TNF inhibitor] treatment plays a protective role in PsA development in severe psoriasis ...

Interleukin-23 inhibitors, prior treatment history, and Psoriasis Area and Severity Index scores may be predictive of time to disease relapse among patients with psoriasis who achieved clinical ...

Of the 230 patients who received continuous deucravacitinib treatment and achieved PASI 75 by week 24, 60.9% achieved PASI 90 and 82.2% achieved sPGA 0/1. Response rates were generally maintained ...

In the analysis, 77% and 75% of patients had an absolute PASI score of 3 or lower at 6 and 12 months, respectively. An absolute PASI of 1 or lower was achieved by 65% and 64% of patients at 6 and ...

A cross-sectional study of 87 patients (mean age, 42.2 years; 24 women) with plaque-type severe psoriasis who went to the dermatology clinic at Gachon University Gil Medical Center, Incheon, South ...

The percentage decrease in PASI score was 65.3% in the apremilast group and 38.3% in the placebo group, which the authors called a significant difference (P < .0001).

Chinese biopharmaceutical company Innovent Biologics has reported that its Phase III CLEAR-1 study of picankibart (IBI112) for treating moderate to severe plaque psoriasis met all its primary and ...

Also, secondary endpoints included a 75% reduction in PASI score (PASI 75) and an IGA score of 0 or 1 (clear or almost clear), along with a 2-point or more improvement in IGA. Of the 202 patients ...

Data of InnoCare's ICP-488 for the Treatment of Psoriasis ... percentage of subjects who achieved at least a 75% improvement from baseline in the Psoriasis Area and Severity Index score (PASI ...

Evelo Biosciences Inc. EVLO said Tuesday it’s reviewing its strategic options and exploring partnerships after a Phase 2 study of a treatment for psoriasis failed to meet its main goal.

The study's primary endpoint, the difference in the proportion of patients who achieved an outcome of a 50% improvement from baseline in Psoriasis Area and Severity Index (PASI) score (a PASI-50 ...